Sales Trainer for PGXL Laboratories

Slides:



Advertisements
Similar presentations
Taking Research and Development to the Clinic: Issues for Physicians AAAS/FDLI Colloquium I Diagnostics and Diagnoses Paths to Personalized Medicine Howard.
Advertisements

ACCF/AHA Clopidogrel Clinical Alert: Approaches to the FDA “Boxed Warning” A Report of the American College of Cardiology Foundation Task Force on Clinical.
Copyright PGXL Laboratories, Louisville KY All materials herein are the exclusive property of PGXL Laboratories PGXL Panels August 2013 Kristen.
CZ5225 Methods in Computational Biology Lecture 9: Pharmacogenetics and individual variation of drug response CZ5225 Methods in Computational Biology.
FDA Pharmacogenetic Labels A Clinical Perspective David A Flockhart MD, PhD Indiana University School of Medicine Clinical Pharmacology Subcommittee of.
1 How New Insights into Pharmacogenomics Lead to Revisions of Product Labels Shiew-Mei Huang, Ph.D. Deputy Director for Science Office of Clinical Pharmacology.
Walsall Healthcare NHS Trust Medicines Management.
Disease State Management The Pharmacist’s Role
Cap.org v. # Pathologists’ Role in Coordinated Care and Managing Patient Populations.
Pharmacogenetics and the Management of Breast Cancer: Optimization of Tamoxifen Therapy Mark E. Sobel, M.D., Ph.D. Executive Officer American Society for.
“Empowerment At The Source of Treatment” Psychotropic & Unnecessary Medication Reduction: Rethinking Your Pathway To compliance.
Mark W Linder, Ph.D., DABCC, FACB Medical Director, EVP Operations Kristen K. Reynolds Ph.D. Associate Medical Director, VP Laboratory Operations Mark.
A Look at Personalized Medicine Quality Assurance Specialist
Clinical Genotyping and Personalized Medicine Michael D. Kane, PhD (1) Associate Professor of Bioinformatics (2) University Faculty Scholar (3) Chair of.
OPTIMISING MEDICINES USE GRAHAM DAVIES Professor of Clinical Pharmacy & Therapeutics Institute of Pharmaceutical Science King’s College London.
Personalized Medicine
Cancer Program Standards 2012: Ensuring Patient-Centered Care
Individualized Medicine Pharmacogentics
Genetic Testing in Genomic Medicine Gail H. Vance M.D. Professor, Department of Medical & Molecular Genetics Indiana University School of Medicine.
Kenneth Sisco, MD, PhD, FCAP Medical Director Quest Diagnostics
University of Utah Department of Human Genetics Pharmacogenomics Louisa A. Stark, Ph.D. Director.
Who Are We? Molecular Testing Labs is a cutting-edge molecular and genetics testing laboratory focused on pharmacogenomics. Our primary goal is to provide.
Kristen K. Reynolds, PhD Associate Medical Director, VP Laboratory Operations Copyright 2010 PGXL Laboratories LLC, Louisville KY All materials herein.
Implementing pharmacogenetics with CIPHER™ Personalized Medicine Program Property of PGxl Laboratories Kristen K. Reynolds, PhD VP Laboratory Operations.
Introduction to Precision Medicine
The University of Mississippi Medical Center
Copyright PGXL Laboratories, Louisville KY All materials herein are the exclusive property of PGXL Laboratories PGX Applications in Pain Management.
IF:Pain © PGXL Laboratories. Pain Management - Opioids Problem and Implications 2% to 40% of adults suffer from chronic pain 1 90% of patients.
Pharmacogenomics Eric Jorgenson.
Preventing Surgical Complications Prevent Harm from High Alert Medication- Anticoagulants in Primary Care Insert Date here Presenter:
“Empowerment At The Source of Treatment” Psychotropic & Unnecessary Medication Reduction: Rethinking Your Pathway To compliance.
Foot and Ankle Specialist practicing for over 30 years in the Hudson Valley. Operates six successful practices in the New York Market. His passion has.
Opioid Use: What are the technological, clinical, ethical, and regulatory issues? Michael Von Korff Group Health Research Institute.
Biomedical Research.
Precision Medicine A New Initiative. The Concept of Precision Medicine (PM) The prevention and treatment strategies that take individual variability into.
SHAWN KISE, BSN, RN May 14 th 2012 Wright State University CVD IN MIDDLE AGE MEN.
IF:Cardiovascular © PGXL Laboratories.
Genomic Health, Inc. Yuko Soneoka, Ph.D., J.D. Senior Corporate Counsel, IP Director of Intellectual Property January 31, 2013.
POLICY DILEMMAS IN GENOMICS AND INTERNATIONAL HEALTH POLICY Elettra Ronchi, PhD
Pharmacogenetics & Pharmacogenomics Personalized Medicine.
Aspirin Resistance: Significance, Detection and Clinical Management of This Real Phenomenon Webcast May 10 th, 2004 Sponsored by.
Definitions. Clinical pharmacy is the branch of Pharmacy where pharmacists provide patient care that optimizes the use of medication and promotes health,
NPS MEDICINEWISE Lynn Weekes Chief Executive.
Personalized Medicine Dr. M. Jawad Hassan. Personalized Medicine Human Genome and SNPs What is personalized medicine? Pharmacogenetics Case study – warfarin.
Bringing Genomics Home Your DNA: A Blueprint for Better Health Dr. Brad Popovich Chief Scientific Officer Genome British Columbia March 24, 2015 / Vancouver,
UIPS Utrecht Institute for Pharmaceutical Sciences Priority Medicines for Europe and the World: Cross-cutting themes Hubert G. Leufkens.
HUMAN GENOME PROJECT International effort of 13 years (1990 – 2003) Identified all the approximate 20,000 – 25,000 genes in human DNA Determined the sequences.
They deserve personalized treatment Your patients are unique.
D4FF55A0-6B6F BF422A9BA9 Present by: Xiao Chen On December 7, 2015.
Pharmacogenetics.
Challenges to drug design Did you know? Over 2 million people are hospitalized each year for adverse reactions to prescription drugs. Over 2 million.
How Genetic Variants Impact the Safety and Effectiveness of Drugs Pharmacogenetics © PGXL Laboratories.
Introduction to Pharmacology Yacoub Irshaid MD, PhD, ABCP Department of Pharmacology.
Pharmacogenetics (PGx) of Irinotecan: Scientific and Clinical Impact of UGT Polymorphism: Background Clinical Pharmacology Subcommittee of ACPS November.
Sports Nutrition Introduction. Sports Nutrition There are two main points that this class will be focusing on. 1. The role nutrition and exercise play.
Pharmacogenomics: Improving the Dynamic of Care in Medication Management 1.
A Cost-Effectiveness Analysis of Maternal Genotyping to Guide Treatment in Postnatal Patients.
Genomic Medicine Rebecca Tay Oncology Registrar. What is Genomic Medicine? personalised, precision or stratified medicine.
Pharmacogenomics based personalized medicine: Are the standards of evidence requirements different from standards for Clinical-Based Personalized Medicine?
Pharmacogenetics/Pharmacogenomics. Outline Introduction  Differential drug efficacy  People react differently to drugs Why does drug response vary?
How Do We Individualize Guidelines in an Era of Personalized Medicine? Douglas K. Owens, MD, MS VA Palo Alto Health Care System Stanford University, Stanford.
Moiz Bakhiet, MD, PhD, Professor and Chairman
New research areas in personalised medicines
PGx Logical Overview.
Pharmacogenomics: towards personalized medicine
Pharmacogenetic effects on pharmacokinetics and pharmacodynamics
Precision Oncology Carolyn M. Hutter, PhD.
Beatriz Pérez González 2017/18 Genomics
Pharmacogenomics Genes and Drugs.
Clair Huckerby Consultant Pharmacist
Presentation transcript:

Sales Trainer for PGXL Laboratories 502-836-3361 Kim Dolan Sales Trainer for PGXL Laboratories 502-836-3361

The Human Genome © 2009 - 2014 PGXL Laboratories

Human Genome Research Initiative “As important a breakthrough as understanding human anatomy” Francis Collins, Director National Institutes of Health Goals Determine the sequence of chemical pairs that make up Human DNA Identify and map the 25,000 genes and 3.1 million base pairs of the human genome from a physical and functional standpoint Understand genes and how they work to understand how diseases are caused and how best to cure them Switch from reacting to a disease to prevention

Evolution of Pharmacogenetics PGXL Founders Are Pioneers in the Field 1988 – International Human Genome Initiative (HGRI) launched 1989 – Dr. Roland Valdes launches post-PhD Molecular Clinical Chemistry program 1993 – Dr. Francis Collins assumes leadership of HGRI 1997 – Dr. Valdes and Dr. Mark Linder publish seminal pharmacogenetics paper Continued…

Evolution of Pharmacogenetics PGXL Founders Are Pioneers in the Field 2001 – PGXL Laboratories is first CLIA-certified pharmacogenetics specialist in U.S. 2004 – Human genome sequenced and published 2010 – Drs. Valdes and Linder publish guidelines for operating a pharmacogenetics laboratory …Continued

Pharmacogenetics Why It Matters There can be wide variability in patient response to commonly prescribed medications Genetics is estimated to account for 20-95% of the variability in drug effects Adverse Drug Reactions (ADRs) are the 6th leading cause of death A review of drugs most commonly associated with ADRs found that 57% (16 of 27) were metabolized by a gene with a known genetic polymorphism

Current Situation/Implications 57% of meds in top 20 list causing ADRs are linked to a genetic variation 20-90% variability in patient response to medications can be explained by genetics >120 drugs have FDA box warnings related to genetics Lazarou et al. JAMA 1998; 279:1200-1205; Phillips KA et al JAMA 2001;286:2270-2279; Kalow W et al. Pharmacogenetics 1998;8:283-289

Pharmacogenetics Same Diagnosis, Same Medications, Different Outcomes Typical Clinic Day N=30 No Variance Normal Response Variance Risk Decreased Variance Lack of Efficacy Variance High Risk

Pharmacogenetics The Study of How Our Genes Affect Our Response to Drugs Every human has a genetic code that is unique to them There is no perfect version of the code; we all have variants Variances in genes responsible for drug metabolism, transport and uptake/binding can: Be of no consequence to the drug’s safety and efficacy Render a medication useless Result in a medication causing serious adverse reactions

Incidence of Genetic Variants Important to Drug Selection and Drug Dose % of Extensive Metabolizers % of Intermediate Metabolizers % of Poor Metabolizers % of Ultra-Rapid Metabolizers VARIANTS 2D6 53% 35% 10% 2% 47% 2C19 36% 32% 4% 28% 64% 2C9 57% 40% 3% NA 43% VKOR >70% 3A4 87% 12% 1% N/A 13% 3A5 18% 81% 99% SLC6A4 25% 50% 75% 1. Pharmacogenetics Knowledge Base Implementation: www.pharmgkb.org Property of PGxl Laboratories

Leading ADRs resulting in hospitalizations Drug group/drug No (%) of cases Individual drugs Adverse reactions NSAIDs 363 (29.6) Aspirin (218), diclofenac (52), ibuprofen (34), rofecoxib (33), celecoxib (8), ketoprofen (6) naproxen (5) GI bleeding, peptic ulceration, haemorrhagic cerebrovascular accident, renal impairment, wheezing, rash Diuretics 334 (27.3) Furosemide (128), bendroflumethiazide (103), bumetanide (43), spironolactone (37), amiloride (19), metolazone (11), indapamide (6) Renal impairment, hypotension, electrolyte disturbances, gout Warfarin 129 (10.5) — GI bleeding, haematuria, high INR, haematoma ACE inhibitors/All receptor antagonists 94 (7.7) Ramipril (28), enalaparil (25), captopril (12), lisinopril (9), irbesartan (6), losartan (5), perindopril (4) Renal impairment, hypotension, electrolyte disturbance, angioedema Antidepressants 87 (7.1) Fluoxetine (17), paroxetine (14), amitriptyline (13), citalopram (9), lithium (8), venlafaxine (8) dosulepin (7) Confusion, hypotension, constipation, GI bleed, hyponataemia β blockers 83 (6.8) Atenolol (69), propranolol (6), sotalol (3), bisoprolol (2), metoprolol (2), carvedilol (1) Bradycardia, heart block, hypotension, wheezing Opiates 73 (6.0) Morphine (20), dihydrocodeine (20), co-codamol (8), tramadol (8), co-dydramol (6), fentanyl (5) Constipation, vomiting, confusion, urinary retention Digoxin 36 (2.9) Symptomatic toxic digoxin levels Prednisolone 31 (2.5) Gastritis, GI bleeding, hyperglycaemia, osteoporotic fracture Clopidogrel 29 (2.4) GI bleeding Pirmohamed et al. BMJ 2004;329(7456):15–9.

State-of-the-Art -- 2014 Cardiovascular Behavioral Health Benefits of Molecular PGx Guided Therapy Decision Making Behavioral Health Treatment Resistant Depression Schizophrenia Cardiovascular Anti-Platelet Activation Anti-Coagulation Pain Management Opioids Patient Improvement Cost Savings Patient Satisfaction & Compliance Risk Reduction

CIPHER™ strength of evidence CV Antiplatelet therapy Anticoagulation management Hyperlipidemia Hypertension/arrhythmia Pain Opioids NSAIDs Muscle relaxants Behavioral Health Treatment-resistant depression (TRD) Psychosis ADHD Internal Med/GP Antithrombotic therapies CV health (arrhythmia, lipids, stroke) Chronic pain management Type II diabetes management GU health Antimicrobials Multidrug sensitivity Oncology (under development) Colorectal cancer (KRAS, BRAF, Lynch) Breast cancer (tamoxifen) Lung Cancer (EGFR, etc) Property of PGxl Laboratories

Personalized Medicine Program PM Program Core Team Creation PGxl & Client Project Planning Meeting Schedule Design Program Launch and Support Program Track and Modify Program